Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) revealed on Wednesday that the US Food and Drug Administration (FDA) has issued a Complete Response Letter relating to the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus.
The FDA requested additional information concerning the manufacturing process and the type 1 diabetes indication.
Novo Nordisk said that it will work closely with the FDA to address the requests but does not expect to be able to do so in 2024.
Insulin icodec is approved for both type 1 and type 2 diabetes in the European Union, Canada, Australia, Japan and Switzerland, and for type 2 diabetes in China.
Xylyx Bio receives SBIR grant from NIDDK
Lilly expands manufacturing footprint in Ireland
Arecor reports positive Phase I Results for AT278 insulin at EASD 2024
Diamyd Medical seeks Fast-Track approval for Type 1 Diabetes immunotherapy
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lifecare sensor achieves 9-week longevity in dog trial
RedHill Biopharma reports promising results for opaganib in obesity and diabetes studies
Sumitomo Pharma and Poxel report positive results from TWYMEEG study in Japan
Sapphiros names new chief financial officer
Amylyx receives EU Orphan Drug Designation for Wolfram syndrome treatment
KVK Tech registers Lomaira 8mg tablets in Mexico
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
M8 Pharmaceuticals signs exclusive licensing and distribution agreement with LG Chem